<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04239807</url>
  </required_header>
  <id_info>
    <org_study_id>GALILEO-HFpEF-Home</org_study_id>
    <nct_id>NCT04239807</nct_id>
  </id_info>
  <brief_title>3-Month Home-based Training With Whole Body Vibration (WBV) Device in Patients With Heart Failure and Preserved Ejection Fraction (GALILEO-HFpEF-HOME) (GALILEOHOME)</brief_title>
  <acronym>GALILEO-HFpEF</acronym>
  <official_title>3-Month Home-based Training With Whole Body Vibration Device in Patients With Heart Failure and Preserved Ejection Fraction (GALILEO-HFpEF-HOME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universität Köln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Stiftung für Herzforschung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum der Universität Köln</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to evaluate Long-term effects of whole Body Vibration (wbv) in patients with HFpEF&#xD;
      patients will get a training device to use at home for 3 months. Patients in the Intervention&#xD;
      group will be introduced in the training program on the wbv-device in the study center 3-4&#xD;
      times and baseline parameters will be collected before start of the home based training.&#xD;
      Patients randomized into the placebo arm be introduced into the training program according to&#xD;
      the interventional arm but not performing the exercises on the wbv-device but on the floor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion&#xD;
      criteria&#xD;
&#xD;
      Randomization (day -7): Subjects will be randomized to either Intervention Group (training on&#xD;
      wbv platform) or non-Intervention Group (training without wbv).&#xD;
&#xD;
      Introduction Week -1(-7d-d1): All subjects will receive introduction in their training&#xD;
&#xD;
      Month 1:&#xD;
&#xD;
      Day 1: From this day subjects are supposed to start their training according to protocol&#xD;
&#xD;
      Day 2: Telephone Visit&#xD;
&#xD;
      Day 5: Telephone Visit&#xD;
&#xD;
      Day 7: Telephone Visit&#xD;
&#xD;
      Day 10: Telephone Visit&#xD;
&#xD;
      Day 13: Telephone Visit&#xD;
&#xD;
      Day 20: Telephone Visit&#xD;
&#xD;
      Day 27: Telephone Visit&#xD;
&#xD;
      Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training&#xD;
&#xD;
      Month 2:&#xD;
&#xD;
      Week 5, Day 34:&#xD;
&#xD;
      Week 6, Day 41:&#xD;
&#xD;
      Week 7, Day 48:&#xD;
&#xD;
      Week 8, Day 55:&#xD;
&#xD;
      Month 3:&#xD;
&#xD;
      Week 9, Day 62:&#xD;
&#xD;
      Week 10, Day 69:&#xD;
&#xD;
      Week 11, Day 76:&#xD;
&#xD;
      Week 12, Day 83: Final Visit&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera&#xD;
Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).&#xD;
Introduction Week -1(-7d-d1): All subjects will receive introduction in their training&#xD;
Month 1:&#xD;
Day 1: From this day subjects are supposed to start their training accoridng to protocol&#xD;
Day 2: Telephone Visit&#xD;
Day 5: Telephone Visit&#xD;
Day 7: Telephone Visit&#xD;
Day 10: Telephone Visit&#xD;
Day 13: Telephone Visit&#xD;
Day 20: Telephone Visit&#xD;
Day 27: Telephone Visit&#xD;
Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training&#xD;
Month 2:&#xD;
Week 5, Day 34:&#xD;
Week 6, Day 41:&#xD;
Week 7, Day 48:&#xD;
Week 8, Day 55:&#xD;
Month 3:&#xD;
Week 9, Day 62:&#xD;
Week 10, Day 69:&#xD;
Week 11, Day 76:&#xD;
Week 12, Day 83: Final Visit</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Peak Oxygen consumption</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Group 1 WBV - training with wbv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera&#xD;
Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).&#xD;
Introduction Week -1(-7d-d1): All subjects will receive introduction in their training&#xD;
Month 1:&#xD;
Day 1: From this day subjects are supposed to start their training accoridng to protocol&#xD;
Day 2: Telephone Visit&#xD;
Day 5: Telephone Visit&#xD;
Day 7: Telephone Visit&#xD;
Day 10: Telephone Visit&#xD;
Day 13: Telephone Visit&#xD;
Day 20: Telephone Visit&#xD;
Day 27: Telephone Visit&#xD;
Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training&#xD;
Month 2:&#xD;
Week 5, Day 34:&#xD;
Week 6, Day 41:&#xD;
Week 7, Day 48:&#xD;
Week 8, Day 55:&#xD;
Month 3:&#xD;
Week 9, Day 62:&#xD;
Week 10, Day 69:&#xD;
Week 11, Day 76:&#xD;
Week 12, Day 83: Final Visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Control - training without WBV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera&#xD;
Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).&#xD;
Introduction Week -1(-7d-d1): All subjects will receive introduction in their training&#xD;
Month 1:&#xD;
Day 1: From this day subjects are supposed to start their training accoridng to protocol&#xD;
Day 2: Telephone Visit&#xD;
Day 5: Telephone Visit&#xD;
Day 7: Telephone Visit&#xD;
Day 10: Telephone Visit&#xD;
Day 13: Telephone Visit&#xD;
Day 20: Telephone Visit&#xD;
Day 27: Telephone Visit&#xD;
Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training&#xD;
Month 2:&#xD;
Week 5, Day 34:&#xD;
Week 6, Day 41:&#xD;
Week 7, Day 48:&#xD;
Week 8, Day 55:&#xD;
Month 3:&#xD;
Week 9, Day 62:&#xD;
Week 10, Day 69:&#xD;
Week 11, Day 76:&#xD;
Week 12, Day 83: Final Visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Group 1 GALILEO WBV</intervention_name>
    <description>3 month home based WBV training</description>
    <arm_group_label>Group 1 WBV - training with wbv</arm_group_label>
    <arm_group_label>Group 2 Control - training without WBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group 2 Control</intervention_name>
    <description>Training on the floor without WBV</description>
    <arm_group_label>Group 1 WBV - training with wbv</arm_group_label>
    <arm_group_label>Group 2 Control - training without WBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  stable (≥ 2 months) symptomatic heart failure with preserved ejection fraction&#xD;
&#xD;
          -  elevated NTproBNP (&gt;= 125 ng/l)&#xD;
&#xD;
          -  NYHA-WHO/FC II or III&#xD;
&#xD;
          -  peakVO2 &lt;25 mL/kg/min&#xD;
&#xD;
          -  LVEF ≥50%&#xD;
&#xD;
          -  E/e' &gt;15 or 15 ≥E/e' &gt;8 and one of the following:&#xD;
&#xD;
             • NT-proBNP &gt;220 ng/L ar atrial fibrillation&#xD;
&#xD;
          -  age ≥18 years&#xD;
&#xD;
          -  symptoms and heart insufficiency medication according to current guidelines and stable&#xD;
             for at least 4 weeks&#xD;
&#xD;
          -  general mental and physical ability to perform the study&#xD;
&#xD;
          -  ability to understand and sign informed consent of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  non cardial origin of symptoms similiar to heart insufficiency&#xD;
&#xD;
          -  normal NTproBNP (&lt; 125 ng/l)&#xD;
&#xD;
          -  relevant chronic obstructive lungdisease ≥ GOLD Stadium III&#xD;
&#xD;
          -  significant anemia (hemoglobin &lt; 11 mg/dl)&#xD;
&#xD;
          -  relevant renal insuffciency (eGFR &lt;30 mL/min/1.73 m2 indexed to BSA)&#xD;
&#xD;
          -  significant peripheral artery disease (Fontaine ≥ IIb)&#xD;
&#xD;
          -  muscolosclettal disease compromising ability to exercise&#xD;
&#xD;
          -  specific cardiomyopathy (e.g.. amyloidosis)&#xD;
&#xD;
          -  hemodynamic relevant, not repaired valvular diseases&#xD;
&#xD;
          -  relevant coronary artery disease (angina pectoris ≥ CCS II or positive functional&#xD;
             test, myocardial infarction or CABG within last 3 months)&#xD;
&#xD;
          -  unability to perform exercises (mental, physical) or unability to give infromation&#xD;
             requested (diary, quality of life)&#xD;
&#xD;
          -  uncontrolled arterial hypertension (≥140/90 mmHg or ≥160/100 mmHg with 3&#xD;
             antihypertensive substances) or resting heart rate ≥ 100 b.p.m.)&#xD;
&#xD;
          -  unabilty to perform training within time planned (planned vacation)&#xD;
&#xD;
          -  Rehabilitation program or planned new training program 2 months before screeninig or&#xD;
             within the studyphase&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  acute thrombosis (within the last 3 months)&#xD;
&#xD;
          -  Implants in hib, knee or spine (TEP)&#xD;
&#xD;
          -  new fracture (within 3 months)&#xD;
&#xD;
          -  not feasable to perform trianing (NYHA IV, immobility)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>January 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universität Köln</investigator_affiliation>
    <investigator_full_name>Felix Gerhardt</investigator_full_name>
    <investigator_title>Felix Gerhardt, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

